4322

Computational Tool for the Design of a Personalized Protocol for Cancer Therapy, Based on Protein Expression

Kravchenko-Balasha Nataly , HUJI, Faculty of Dental Medicine, Institute of Dental Sciences

Category

Medical Device, BioInformatics, Oncology/Cancer

Highlights

This technology provides a way to design patient-specific drug combinations through an accurate tumor classification, such that every single tumor can be mapped precisely and unambiguously according to the molecular aberrations that it harbors.

Our Innovation 

  • Addressing individual patients, in the opposite to conventional statistical analysis method relating to pre-defined categories of the patient population
  • Once the information from multiple patients is transformed into a low-dimensional space, the technology can provide patient-specific unbalanced network structures. These structures can be used to rationally design patient specific drug therapies.
  • Prediction of direction change in biological systems, thereby generating rationalized strategies for the manipulation of their phenotypes.

Technology

The developed algorithm allows to decoding of altered molecules as well as the structure of the altered molecular networks in each tumor. Specifically, the patient-specific signaling signature, representing the flow of cellular information. The algorithm predicts drug combinations that will target particular components of these networks, in order to restore balance, and correct the tissues, preferentially by killing the tumor cell.

4322.jpg 

Algorithm Workflow

Opportunity

  • Accurate resolution of patient-specific network structures, or a patient-specific signaling protein network signature.
  • The algorithm helps clinicians to rationally design patient-specific drug combinations. Inhibition of the entire set of tumor-specific processes should stop the disease and significantly decrease the chances for the development of drug resistance.

Current development stage

TRL 5 – Alpha testing for of the software by in-house developers/testers

The plan is to extend the approach above to additional cancer types, in vivo animal models and patient derived cancer tissues.

 

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
+972-2-6586608